Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Checkpoint Inhibitors | Research

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study

Authors: Xin Tang, Wen-lei Qian, Wei-feng Yan, Tong Pang, You-ling Gong, Zhi-gang Yang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Tumor mutation burden (TMB) is an emerging prognostic biomarker of immunotherapy for bladder cancer (BLCA). We aim at investigating radiomic features’ value in predicting the TMB status of BLCA patients.

Methods

Totally, 75 patients with BLCA were enrolled. Radiomic features extracted from the volume of interest of preoperative pelvic contrast-enhanced computed tomography (CECT) were obtained for each case. Unsupervised hierarchical clustering analysis was performed based on radiomic features. Sequential univariate Logistic regression, the least absolute shrinkage and selection operator (LASSO) regression and the backward stepwise regression were used to develop a TMB-predicting model using radiomic features.

Results

The unsupervised clustering analysis divided the total cohort into two groups, i.e., group A (32.0%) and B (68.0%). Patients in group A had a significantly larger proportion of having high TMB against those in group B (66.7% vs. 41.2%, p = 0.039), indicating the intrinsic ability of radiomic features in TMB-predicting. In univariate analysis, 27 radiomic features could predict TMB. Based on six radiomic features selected by logistic and LASSO regression, a TMB-predicting model was built and visualized by nomogram. The area under the ROC curve of the model reached 0.853. Besides, the calibration curve and the decision curve also revealed the good performance of the model.

Conclusions

Our work firstly proved the feasibility of using radiomics to predict TMB for patients with BLCA. The predictive model based on radiomic features from pelvic CECT has a promising ability to predict TMB. Future study with a larger cohort is needed to verify our findings.

Available only for authorised users

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50. https://doi.org/10.1038/s41568-019-0116-x.CrossRefPubMedPubMedCentral

Aggen DH, Drake CG. Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer. 2017;5(1):94. https://doi.org/10.1186/s40425-017-0299-1.CrossRefPubMedPubMedCentral

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, version 3.2020. NCCN Clin Pract Guidel Oncol. 2020;18(3):329–54.

Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. https://doi.org/10.3322/caac.21596.CrossRefPubMed

Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F. Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts. Eur J Cancer. 2020;131:40–50. https://doi.org/10.1016/j.ejca.2020.02.038.CrossRefPubMed

Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in Cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56. https://doi.org/10.1158/1535-7163.Mct-14-0983.CrossRef

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20. https://doi.org/10.1016/s0140-6736(16)00561-4.CrossRefPubMedPubMedCentral

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–6. https://doi.org/10.1038/s41588-018-0312-8.CrossRefPubMedPubMedCentral

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung Cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–41. https://doi.org/10.1200/jco.2017.75.3384.CrossRefPubMedPubMedCentral

10.

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al. Tumor mutational burden and efficacy of Nivolumab Monotherapy and in combination with Ipilimumab in small-cell lung Cancer. Cancer Cell. 2019;35(2):329. https://doi.org/10.1016/j.ccell.2019.01.011.CrossRefPubMed

11.

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99. https://doi.org/10.1056/NEJMoa1406498.CrossRefPubMedPubMedCentral

12.

Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67–76. https://doi.org/10.1016/s0140-6736(16)32455-2.CrossRefPubMed

13.

Galsky M, Saci A, Szabo P, Azrilevich A, Horak C, Lambert A, et al. Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase ii checkmate 275 study. Ann Oncol. 2017;28:v296–v7. https://doi.org/10.1093/annonc/mdx371.003.CrossRef

14.

Avanzo M, Stancanello J, El Naqa I. Beyond imaging: the promise of radiomics. Phys Med. 2017;38:122–39. https://doi.org/10.1016/j.ejmp.2017.05.071.CrossRefPubMed

15.

Yang L, Dong D, Fang M, Zhu Y, Zang Y, Liu Z, et al. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? Eur Radiol. 2018;28(5):2058–67. https://doi.org/10.1007/s00330-017-5146-8.CrossRefPubMed

16.

Li ZC, Bai H, Sun Q, Zhao Y, Lv Y, Zhou J, et al. Multiregional radiomics profiling from multiparametric MRI: identifying an imaging predictor of IDH1 mutation status in glioblastoma. Cancer Med. 2018;7(12):5999–6009. https://doi.org/10.1002/cam4.1863.CrossRefPubMedPubMedCentral

17.

Tu W, Sun G, Fan L, Wang Y, Xia Y, Guan Y, et al. Radiomics signature: a potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology. Lung Cancer. 2019;132:28–35. https://doi.org/10.1016/j.lungcan.2019.03.025.CrossRefPubMed

18.

Zhang N, Wu J, Yu J, Zhu H, Yang M, Li R. Integrating imaging, histologic, and genetic features to predict tumor mutation burden of non-small-cell lung Cancer. Clin Lung Cancer. 2020;21(3):e151–e63. https://doi.org/10.1016/j.cllc.2019.10.016.CrossRefPubMed

19.

Wang X, Kong C, Xu W, Yang S, Shi D, Zhang J, et al. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature. Thorac Cancer. 2019;10(10):1904–12. https://doi.org/10.1111/1759-7714.13163.CrossRefPubMedPubMedCentral

20.

Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer imaging archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013;26(6):1045–57. https://doi.org/10.1007/s10278-013-9622-7.CrossRefPubMedPubMedCentral

21.

Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45(10):1113-20. https://doi.org/10.1038/ng.2764.

22.

Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging. 2012;30(9):1323–41. https://doi.org/10.1016/j.mri.2012.05.001.CrossRefPubMedPubMedCentral

23.

Mahon R, Ghita M, Hugo G, Weiss E. ComBat harmonization for radiomic features in independent phantom and lung cancer patient computed tomography datasets. Phys Med Biol. 2020;65(1):015010. https://doi.org/10.1088/1361-6560/ab6177.CrossRefPubMed

24.

Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, et al. A Postreconstruction harmonization method for multicenter Radiomic studies in PET. J Nucl Med. 2018;59(8):1321–8. https://doi.org/10.2967/jnumed.117.199935.CrossRefPubMed

25.

Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. https://doi.org/10.1186/s13073-017-0424-2.CrossRefPubMedPubMedCentral

26.

Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Tamborero D, Schroeder MP, Jene-Sanz A, et al. IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods. 2013;10(11):1081–2. https://doi.org/10.1038/nmeth.2642.CrossRefPubMedPubMedCentral

27.

Wang H, Hu D, Yao H, Chen M, Li S, Chen H, et al. Radiomics analysis of multiparametric MRI for the preoperative evaluation of pathological grade in bladder cancer tumors. Eur Radiol. 2019;29(11):6182–90. https://doi.org/10.1007/s00330-019-06222-8.CrossRefPubMed

28.

Lim CS, Tirumani S, van der Pol CB, Alessandrino F, Sonpavde GP, Silverman SG, et al. Use of quantitative T2-weighted and apparent diffusion coefficient texture features of bladder Cancer and Extravesical fat for local tumor staging after transurethral resection. AJR Am J Roentgenol. 2019;212(5):1–10. https://doi.org/10.2214/ajr.18.20718.CrossRef

29.

Wu S, Zheng J, Li Y, Wu Z, Shi S, Huang M, et al. Development and validation of an MRI-based Radiomics signature for the preoperative prediction of lymph node metastasis in bladder Cancer. EBioMedicine. 2018;34:76–84. https://doi.org/10.1016/j.ebiom.2018.07.029.CrossRefPubMedPubMedCentral

30.

Xu X, Wang H, Du P, Zhang F, Li S, Zhang Z, et al. A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors. J Magn Reson Imaging. 2019;50(6):1893–904. https://doi.org/10.1002/jmri.26749.CrossRefPubMedPubMedCentral

31.

Lin P, Wen DY, Chen L, Li X, Li SH, Yan HB, et al. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. Eur Radiol. 2020;30(1):547–57. https://doi.org/10.1007/s00330-019-06371-w.CrossRefPubMed

32.

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1. https://doi.org/10.1056/NEJMc1713444.CrossRefPubMedPubMedCentral

33.

Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, et al. Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study. J Thorac Oncol. 2020;15(7):1177–89. https://doi.org/10.1016/j.jtho.2020.01.023.CrossRefPubMed

34.

Zhuang W, Ma J, Chen X, Wang G, Lu J, Chen Y, et al. The tumor mutational burden of Chinese advanced Cancer patients estimated by a 381-cancer-gene panel. J Cancer. 2018;9(13):2302–7. https://doi.org/10.7150/jca.24932.CrossRefPubMedPubMedCentral

Title: Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study
Authors: Xin Tang
Wen-lei Qian
Wei-feng Yan
Tong Pang
You-ling Gong
Zhi-gang Yang
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Checkpoint Inhibitors
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08569-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Trends in incidence and histological pattern of thyroid cancer in Ho Chi Minh City, Vietnam (1996–2015): a population-based study

Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing

Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits

Keynote webinar | Spotlight on antibody–drug conjugates in cancer